LCAT and coronary artery disorder: The CSL112 and LCAT infusions are the most promising of the infusion therapies, but studies are needed to investigate the effects of CSL112 on CHD risk markers, including vessel wall characteristics and inflammation, and LCAT infusions need to be investigated in clinical trials with more patients.